Federated Hermes Inc. Decreases Position in Keros Therapeutics, Inc. $KROS

Federated Hermes Inc. lessened its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 21.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 514,160 shares of the company’s stock after selling 139,870 shares during the period. Federated Hermes Inc.’s holdings in Keros Therapeutics were worth $8,134,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. AQR Capital Management LLC purchased a new stake in Keros Therapeutics in the first quarter valued at approximately $226,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Keros Therapeutics by 15.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company’s stock valued at $227,000 after purchasing an additional 2,982 shares during the period. Goldman Sachs Group Inc. raised its holdings in Keros Therapeutics by 38.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock worth $7,547,000 after purchasing an additional 205,022 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new stake in shares of Keros Therapeutics in the 2nd quarter worth about $348,000. Finally, CWM LLC increased its position in shares of Keros Therapeutics by 87.5% during the second quarter. CWM LLC now owns 5,000 shares of the company’s stock valued at $67,000 after buying an additional 2,333 shares during the period. Institutional investors own 71.56% of the company’s stock.

Wall Street Analysts Forecast Growth

KROS has been the topic of several recent research reports. Oppenheimer reaffirmed an “outperform” rating and issued a $27.00 price target (up from $23.00) on shares of Keros Therapeutics in a research note on Wednesday, November 12th. TD Cowen raised shares of Keros Therapeutics to a “hold” rating in a report on Friday, December 19th. Bank of America lifted their target price on Keros Therapeutics from $18.00 to $19.00 and gave the company a “neutral” rating in a research report on Friday, November 28th. Zacks Research cut Keros Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 1st. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Keros Therapeutics in a research note on Monday, December 29th. Five research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Keros Therapeutics presently has a consensus rating of “Hold” and an average target price of $22.29.

Keros Therapeutics Price Performance

NASDAQ:KROS opened at $17.91 on Monday. The business has a 50 day simple moving average of $19.50 and a 200-day simple moving average of $16.78. Keros Therapeutics, Inc. has a 1 year low of $9.12 and a 1 year high of $22.55. The firm has a market capitalization of $545.57 million, a price-to-earnings ratio of 11.63 and a beta of 0.86.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, November 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.11) by $0.93. Keros Therapeutics had a return on equity of 9.51% and a net margin of 26.12%.The business had revenue of $14.26 million during the quarter, compared to analyst estimates of $4.22 million. During the same quarter in the previous year, the business earned ($1.41) earnings per share. The company’s revenue for the quarter was up 3585.6% compared to the same quarter last year. As a group, analysts expect that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.